美国的年度癌症筛查成本
The Annual Cost of Cancer Screening in the United States
影响因子:15.20000
分区:医学1区 Top / 医学：内科1区
发表日期:2024 Sep
作者:
Michael T Halpern, Benmei Liu, Douglas R Lowy, Samir Gupta, Jennifer M Croswell, V Paul Doria-Rose
摘要
癌症具有实质性的健康，生活质量和经济影响。筛查可能会降低癌症的死亡率和治疗成本，但在美国进行筛查的成本尚不清楚。估计2021年美国初始癌症筛查的年度成本（即，筛查无随访成本）。使用国家保健调查和资源数据，模型。U.S.卫生保健系统和机构。有资格使用可用数据的乳房，宫颈，结直肠，肺和前列腺癌筛查。估计，估计2021年初始癌症筛查的筛查的人数和相关的医疗保健系统成本为2021美元。大约88.3％的费用归因于私人保险； Medicare 8.5％；以及医疗补助，其他政府计划和未保险人的3.2％。结直肠癌的筛查约占总成本的64％；结肠镜检查约占总数的55％。设施成本（已支付给进行测试的设施的金额）是筛查总估计成本的主要驱动因素。所有收到癌症筛查的数据均基于国家医疗保健调查的自我报告。估计不包括阳性或异常筛查结果的随访成本。基于地理位置和医疗保健组织的成本差异未完全捕获。估计在诊断后的头12个月中，美国估计430亿美元的估计每年对美国初始癌症筛查的年度费用少于美国癌症治疗的年度费用。识别癌症筛查成本及其驱动因素对于帮助政策和制定计划优先级至关重要，特别是对于增强推荐的癌症筛查服务的机会。
Abstract
Cancer has substantial health, quality-of-life, and economic impacts. Screening may decrease cancer mortality and treatment costs, but the cost of screening in the United States is unknown.To estimate the annual cost of initial cancer screening (that is, screening without follow-up costs) in the United States in 2021.Model using national health care survey and cost resources data.U.S. health care systems and institutions.People eligible for breast, cervical, colorectal, lung, and prostate cancer screening with available data.The number of people screened and associated health care system costs by insurance status in 2021 dollars.Total health care system costs for initial cancer screenings in the United States in 2021 were estimated at $43 billion. Approximately 88.3% of costs were attributable to private insurance; 8.5% to Medicare; and 3.2% to Medicaid, other government programs, and uninsured persons. Screening for colorectal cancer represented approximately 64% of the total cost; screening colonoscopy represented about 55% of the total. Facility costs (amounts paid to facilities where testing occurred) were major drivers of the total estimated costs of screening.All data on receipt of cancer screening are based on self-report from national health care surveys. Estimates do not include costs of follow-up for positive or abnormal screening results. Variations in costs based on geography and provider or health care organization are not fully captured.The $43 billion estimated annual cost for initial cancer screening in the United States in 2021 is less than the reported annual cost of cancer treatment in the United States in the first 12 months after diagnosis. Identification of cancer screening costs and their drivers is critical to help inform policy and develop programmatic priorities, particularly for enhancing access to recommended cancer screening services.None.